MedPath

Retorna Facial Cream in the Treatment of Facial Wrinkles

Phase 3
Completed
Conditions
Facial Wrinkles
Interventions
Other: Retorna
Other: Placebo
Registration Number
NCT00978887
Lead Sponsor
Catalysis SL
Brief Summary

The purpose of the study is to assess the efficacy of Retorna facial cream usage in the reduction or total correction of facial wrinkles. The duration of this double-blind placebo controlled phase 3 clinical trial will be 4 weeks. The estimated number of women to be recruited and randomized for the study is 148. Occurrence of adverse effects will also be evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
148
Inclusion Criteria
  • Facial wrinkles
  • Signed informed consent
  • Given verbal agreement on solar exposure prevention within hours of intense solar radiation (10 am - 4 pm) by the usage of physical protection methods such as umbrellas, caps and hats.
Exclusion Criteria
  • Pregnancy
  • Breast-feeding
  • Use of steroids within 6 months.
  • Patients under other experimental treatment
  • Decompensated concomitant diseases
  • Malignant neoplastic conditions.
  • Alcoholism
  • Handicap and/or psychiatric condition preventing treatment accomplishment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ARetornaRetorna (facial cream)
BPlaceboPlacebo (facial cream)
Primary Outcome Measures
NameTimeMethod
Total correction or improvement of facial wrinkles at the end of treatment (4 weeks)4 weeks
Secondary Outcome Measures
NameTimeMethod
Presence of adverse effects within the 4 week treatment period4 weeks

Trial Locations

Locations (1)

"Commander Manuel Fajardo Rivero" Hospital

🇨🇺

Havana City, Havana, Cuba

© Copyright 2025. All Rights Reserved by MedPath